Want to see IN:SHILPAMED full AI Analyst Report?
SHILPAMED Stock Chart & Stats
₹319.90
-₹8.10(-0.96%)
At close: 4:00 PM EST
₹319.90
-₹8.10(-0.96%)
Day’s Range― - ―
52-Week Range₹260.00 - ₹650.00
Previous CloseN/A
Volume218.26K
Average Volume (3M)38.83K
Market Cap
₹121.17B
Enterprise Value₹79.50K
Total Cash (Recent Filing)₹451.80M
Total Debt (Recent Filing)₹6.60B
Price to Earnings (P/E)50.3
Beta0.74
Next Earnings
Aug 06, 2026Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)12.44
Shares Outstanding195,581,820
10 Day Avg. Volume85,780
30 Day Avg. Volume38,829
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.63
Price to Sales (P/S)4.43
P/FCF Ratio-90.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)13.55
Revenue Forecast (FY)₹18.29B
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelShilpa Medicare’s mix of APIs, finished dosages, specialty/generic drugs and contract manufacturing creates multiple durable revenue streams. This diversification reduces single-product risk, captures outsourcing demand from global pharma, and supports stable long-term commercial scale across markets.
Accelerating Revenue And MarginsThe company’s FY2026 rebound—accelerating revenue and materially higher operating and net margins—indicates improved operational leverage and pricing or mix benefits. If sustained, these margin gains can fund reinvestment, improve competitiveness in specialty generics, and raise normalized earnings power.
Conservative Balance SheetRelatively low leverage and growing equity provide financial flexibility to fund capex, R&D or inorganic opportunities without over-reliance on short-term debt. A conservative balance sheet cushions operational downturns and supports medium-term investments critical in pharmaceuticals.
Bears Say
Consistent Negative Free Cash FlowPersistent negative FCF means reported profits are not translating into surplus cash after investments. Over months this forces external financing or asset sales, constrains dividend or buyback capacity, and undermines the durability of earnings unless cash conversion is structurally improved.
Weak Operating Cash CoverageOperating cash that doesn’t cover investment and financing needs signals high working-capital or capex intensity. This structural shortfall limits organic expansion, increases refinancing risk and makes performance sensitive to cash-cycle swings, reducing long-term financial resilience.
Volatile Profitability And Weak ROE HistoryMeaningful swing in margins and historically low ROE indicate earnings have been cyclical and execution inconsistent. Such volatility raises doubt that recent margin improvements are sustained structurally, making returns on invested capital and shareholder value generation less predictable.
Shilpa Medicare Limited News
SHILPAMED FAQ
What was Shilpa Medicare Limited’s price range in the past 12 months?
Shilpa Medicare Limited lowest stock price was ₹260.00 and its highest was ₹650.00 in the past 12 months.
What is Shilpa Medicare Limited’s market cap?
Shilpa Medicare Limited’s market cap is ₹121.17B.
When is Shilpa Medicare Limited’s upcoming earnings report date?
Shilpa Medicare Limited’s upcoming earnings report date is Aug 06, 2026 which is in 15 days.
How were Shilpa Medicare Limited’s earnings last quarter?
Shilpa Medicare Limited released its earnings results on May 22, 2026. The company reported ₹5.5 earnings per share for the quarter, beating the consensus estimate of ₹3.3 by ₹2.2.
Is Shilpa Medicare Limited overvalued?
According to Wall Street analysts Shilpa Medicare Limited’s price is currently Overvalued.
Does Shilpa Medicare Limited pay dividends?
Shilpa Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.08%. See more information on Shilpa Medicare Limited dividends here
What is Shilpa Medicare Limited’s EPS estimate?
Shilpa Medicare Limited’s EPS estimate is 4.
How many shares outstanding does Shilpa Medicare Limited have?
Shilpa Medicare Limited has 195,581,820 shares outstanding.
What happened to Shilpa Medicare Limited’s price movement after its last earnings report?
Shilpa Medicare Limited reported an EPS of ₹5.5 in its last earnings report, beating expectations of ₹3.3. Following the earnings report the stock price went up 3.778%.
Which hedge fund is a major shareholder of Shilpa Medicare Limited?
Currently, no hedge funds are holding shares in IN:SHILPAMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shilpa Medicare Limited
Shilpa Medicare Limited, including its various subsidiaries, manufactures and distributes a range of active pharmaceutical ingredients (APIs), intermediate compounds, and finished drug formulations. Operating across India, the United States, Europe, and other international markets, their product lineup encompasses both oncology and non-oncology APIs. The company also innovates with new drug delivery systems, biological products such as peptides, and specialized chemicals. Furthermore, Shilpa Medicare provides contract manufacturing services for diverse dosage forms, including tablets, capsules, liquid and lyophilized injectables, and sterile dry powder injectables. Beyond its pharmaceutical operations, the firm also participates in wind power generation. Founded in 1987, Shilpa Medicare Limited maintains its headquarters in Raichur, India.
Technical Analysis
Akums Drugs and Pharmaceuticals Limited
―
Alembic Pharmaceuticals Limited
―
Caplin Point Laboratories Limited
―
Jubilant Pharmova Limited
―
Strides Pharma Science Ltd
―